Yang (2020)
Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension

https://doi.org/10.1101/2020.03.31.20038935
Comorbidities
Hypertension (Present vs. Not present)
COVID-19 (severe/critical)
Odds ratio: 1.770 (0.860-3.620) Univariate analysis. Calculated odds ratio based on data reported in the article.

Retrospective observational study

251

COVID-19 patients with preexisting hypertension at Hubei Provincial Hospital of Traditional Chinese Medicine (HPHTCM) in Wuhan from January 5 to February 22, 2020 and age- and sex-matched COVID-19 patients without hypertension were randomly selected as non-hypertension control

Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension

0


COVID-19 (severe/critical)

0

COVID-19 (critical)


Comorbidities

Hypertension

Not present

Present


Odds ratio

1.770 (0.860-3.620)

No

No

No


No